RxDoctor Payments Data

Madhu Dukkipati, MD

Interventional Cardiology · Macomb, ILNPI 1063436715

Payments from drug & device makers

$6,724in general payments, 2019–2025

Across 244 payments — averaging $27.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Amgen$963
  • Johnson & Johnson$598
  • E.r. Squibb & Sons, L.L.C.$358
  • Abbott$298
  • AstraZeneca$296
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$1,19218%
  • Food & beverage$5,45281%
  • Education$391%
  • Gifts$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,724 in reported general payments places this provider in the 40th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$182,189
Medicare patients
1,594
Services billed
2,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban252$248,200
Repatha SureclickEvolocumab221$220,176
EntrestoSacubitril/Valsartan195$196,793
Praluent PenAlirocumab174$116,609
XareltoRivaroxaban63$68,872
BrilintaTicagrelor37$27,922
JardianceEmpagliflozin16$16,597
Repatha SyringeEvolocumab16$9,862
Metoprolol Succinate607$7,158
Atorvastatin Calcium584$5,002
Rosuvastatin Calcium524$4,850
ClopidogrelClopidogrel Bisulfate367$3,886
Ezetimibe165$2,908
Isosorbide Mononitrate ErIsosorbide Mononitrate256$2,138
Carvedilol312$2,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$197$248,200252 claims
NovartisEntresto$136$196,793195 claims
Johnson & JohnsonXarelto$598$68,87263 claims
AstraZenecaBrilinta$296$27,92237 claims
Boehringer IngelheimJardiance$39$16,59716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Macomb

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →